TY - JOUR
T1 - A study on the PK and BA profiles in the mouse body for leonurine O/O microemulsion with determination by the LC-MS/MS method
AU - Sun, Yanan
AU - Zhang, Xiang
AU - Lu, Tao
AU - Yuan, Yuan
AU - Ding, Qi
AU - Lu, Chuanhua
N1 - Publisher Copyright:
© 2015, Springer International Publishing Switzerland.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Leonurine (LE) has been found to have therapeutic efficacy in cerebral thrombosis, but its poor solubility in water leads to very low bioavailability. In this article, a leonurine O/O microemulsion (LE-ME) was prepared and investigated for its in vivo pharmacokinetic behavior and bioavailability in the mouse body using an aqueous suspension of leonurine (LE-SWW) for the control group. A simple, sensitive and specific method, HPLC-MS/MS, was developed for detection of the LE content in mouse plasma using n-benzoyl-l-arginine ethyl ester as an internal standard. The results demonstrated that the Cmax of LE-ME was 2.46-fold higher than that of the suspension following oral administration. The absolute bioavailability was 10.95 %, while that of the suspension was only 1.78 %. The T1/2β and MRT of LE-ME were 3.04- and 4.19-fold those of the suspension, respectively. In addition, following intramuscular administration of LE-ME, the absolute bioavailability was 37.45 %. The results indicated that LE-ME is a promising drug-delivery system to enhance the absorption and bioavailability of LE.
AB - Leonurine (LE) has been found to have therapeutic efficacy in cerebral thrombosis, but its poor solubility in water leads to very low bioavailability. In this article, a leonurine O/O microemulsion (LE-ME) was prepared and investigated for its in vivo pharmacokinetic behavior and bioavailability in the mouse body using an aqueous suspension of leonurine (LE-SWW) for the control group. A simple, sensitive and specific method, HPLC-MS/MS, was developed for detection of the LE content in mouse plasma using n-benzoyl-l-arginine ethyl ester as an internal standard. The results demonstrated that the Cmax of LE-ME was 2.46-fold higher than that of the suspension following oral administration. The absolute bioavailability was 10.95 %, while that of the suspension was only 1.78 %. The T1/2β and MRT of LE-ME were 3.04- and 4.19-fold those of the suspension, respectively. In addition, following intramuscular administration of LE-ME, the absolute bioavailability was 37.45 %. The results indicated that LE-ME is a promising drug-delivery system to enhance the absorption and bioavailability of LE.
KW - Bioavailability
KW - Leonurine
KW - Microemulsion
KW - Pharmacokinetic
UR - http://www.scopus.com/inward/record.url?scp=84923233639&partnerID=8YFLogxK
U2 - 10.1007/s13318-015-0268-3
DO - 10.1007/s13318-015-0268-3
M3 - Article
C2 - 25698144
AN - SCOPUS:84923233639
SN - 0378-7966
VL - 41
SP - 423
EP - 432
JO - European Journal of Drug Metabolism and Pharmacokinetics
JF - European Journal of Drug Metabolism and Pharmacokinetics
IS - 4
ER -